Triazole DAGLα Inhibitors for Neuroinflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases and neuroinflammatory conditions lack effective modulators for diacylglycerol lipases (DAGL) to regulate brain lipid signaling, which is crucial for synaptic function and behavior.
Innovation Solution
Development of compounds that selectively inhibit DAGLα and/or DAGLβ, modulating their activity to treat neurodegenerative diseases and neuroinflammatory conditions by regulating brain lipid signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodegenerative diseases and neuroinflammatory conditions, then existing therapeutic options are available, but effective modulators for diacylglycerol lipases (DAGL) to regulate brain lipid signaling are lacking
Solution Approach 1:
The patent segments the DAGL enzyme into two distinct isoforms (DAGLα and DAGLβ) and develops selective inhibitors for each. The compounds are designed to differentiate between these isoforms, allowing selective modulation of DAGLα or DAGLβ activity. This segmentation approach enables targeted therapy by addressing specific isoform functions in neurodegenerative and neuroinflammatory conditions.
Solution Approach 2:
The patent employs parameter changes by modifying molecular structures of triazole compounds to achieve different binding affinities and selectivity profiles for DAGLα and DAGLβ. By adjusting structural parameters such as substituent groups on the triazole core, the invention optimizes inhibitor specificity and potency for each isoform, thereby creating versatile modulators for different therapeutic applications.
2Reliability
If DAGL activity is inhibited to treat neurodegenerative diseases and neuroinflammatory conditions, then therapeutic benefits are achieved, but selective inhibition of DAGLα and/or DAGLβ requires specific compound design
Solution Approach 1:
The patent uses triazole compounds as intermediary molecules that mediate the inhibition of DAGLα and/or DAGLβ. These triazole-based inhibitors act as intermediaries between the therapeutic goal (reducing neuroinflammation and treating neurodegenerative diseases) and the molecular target (DAGL enzymes). The triazole core structure serves as a versatile scaffold that can be modified to achieve selective inhibition while maintaining manageable structural complexity.
Data Source
AI summary
Provided herein are triazole compounds and pharmaceutical compositions comprising said compounds useful as modulators of DAGL(α) and DAGL(β). In some embodiments, the compounds described herein are selective DAGL(α) inhibitors. Furthermore, the subject compounds and compositions are useful for the treatment of neurodegenerative or neuroinflammatory disease.